Advertisement

Schmerzmedizin

, Volume 34, Issue 5, pp 21–23 | Cite as

Leserbrief zu Hilscher HJ. Schmerzmedizin 2018; 34 (4): 24–27

„Mögliche Vorteile von Methadon viel zu positiv dargestellt“

  • Constanze Rémi
  • Claudia Bausewein
  • Lukas Radbruch
Fortbildung Leserbriefe

Literatur

  1. 1.
    Raynor K et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Molecular Pharmacology. 1994;45(2):330–4Google Scholar
  2. 2.
    Ebert B et al. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neuroscience Letter. 1995;187:165–8CrossRefGoogle Scholar
  3. 3.
    Gorman AL et al. The d- and l- isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neuroscience Letters. 1997;223:5–8CrossRefGoogle Scholar
  4. 4.
    Matsui A, Williams JT. Activation of micro-opioid receptors and block of Kir3 potassium channels and NMDA receptor conductance by L- and D-methadone in rat locus coeruleus. British journal of pharmacology. 2010;161(6):1403–13CrossRefGoogle Scholar
  5. 5.
    Codd EE et al. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. Journal of Pharmacology and Experimental Therapeutics. 1995;274:1263–70Google Scholar
  6. 6.
    Kafami L et al. Methadone diminishes neuroinflammation and disease severity in EAE through modulating T cell function. Journal of neuroimmunology. 2013;255(1-2):39–44CrossRefGoogle Scholar
  7. 7.
    Hendra T et al. Fatal methadone overdose. British Medical Journal. 1996;313:481–2CrossRefGoogle Scholar
  8. 8.
    Chatham MS et al. Dose ratios between high dose oral morphine or equivalents and oral methadone. Journal of palliative medicine. 2013;16(8):947–50CrossRefGoogle Scholar
  9. 9.
    Mercadante S, Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliative medicine. 2011;25(5):504–15CrossRefGoogle Scholar
  10. 10.
    Benitez-Rosario MA et al. Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors. Journal of Pain and Symptom Management. 2009;37(6):1061–8CrossRefGoogle Scholar
  11. 11.
    Weschules DJ, Bain KT. A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Medicine. 2008;9(5):595–612CrossRefGoogle Scholar
  12. 12.
    Walker PW et al. Switching from methadone to a different opioid: what is the equianalgesic dose ratio? Journal of palliative medicine. 2008;11(8):1103–8CrossRefGoogle Scholar
  13. 13.
    Tse DM et al. An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population. Palliative medicine. 2003;17(2):206–11CrossRefGoogle Scholar
  14. 14.
    Ripamonti C et al. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? Journal of Clinical Oncology. 1998;16(10):3216–21CrossRefGoogle Scholar
  15. 15.
    Freye E. Opioide in der Medizin. 9 ed: Springer Verlag; 2016. p. S. 84-5Google Scholar
  16. 16.
    Lugo RA et al. Pharmacokinetics of methadone. Journal of Pain and Palliative Care Pharmacotherapy. 2005;19(4):13–24CrossRefGoogle Scholar
  17. 17.
    Fisher K et al. Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study. Journal of Pain and Symptom Management. 2004;28(6):619–25CrossRefGoogle Scholar
  18. 18.
    Hagen NA et al. A formal feasibility study of sublingual methadone for breakthrough cancer pain. Palliative medicine. 2010;24(7):696–706CrossRefGoogle Scholar
  19. 19.
    Takase N et al. Methadone for Patients with Malignant Psoas Syndrome: Case Series of Three Patients. Journal of palliative medicine. 2015;18(7):645–52CrossRefGoogle Scholar
  20. 20.
    Sugiyama Y et al. A Retrospective Study on the Effectiveness of Switching to Oral Methadone for Relieving Severe Cancer-Related Neuropathic Pain and Limiting Adjuvant Analgesic Use in Japan. Journal of palliative medicine. 2016;19(10):1051–9CrossRefGoogle Scholar
  21. 21.
    McNicol ED et al. Methadone for neuropathic pain in adults. The Cochrane database of systematic reviews. 2017;5:Cd012499Google Scholar
  22. 22.
    Davis MP et al. When opioids cause pain. Journal of Clinical Oncology. 2007;25(28):4497–8CrossRefGoogle Scholar
  23. 23.
    El Osta B et al. Intractable pain: intoxication or undermedication? Journal of palliative medicine. 2007;10(3):811–4CrossRefGoogle Scholar
  24. 24.
    Gießelmann K. Onkologie: Methadon wirkt unterschiedlich. Deutsches Ärzteblatt. 2018;115(11):480Google Scholar
  25. 25.
    Wirz S et al. Onkologie: Zu viele Fragen offen. Deutsches Ärzteblatt. 2018;115(23):A 1134Google Scholar
  26. 26.
    Bart G et al. Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic study. Drug and alcohol dependence. 2014;145:185–93CrossRefGoogle Scholar
  27. 27.
    Ojanpera I et al. Fatal toxicity index of medicinal drugs based on a comprehensive toxicology database. International journal of legal medicine. 2016;130(5):1209–16CrossRefGoogle Scholar
  28. 28.
    Ray WA et al. Out-of-hospital mortality among patients receiving methadone for noncancer pain. JAMA internal medicine. 2015;175(3):420–7CrossRefGoogle Scholar
  29. 29.
    Arznei-Telegramm. Methadon gegen Krebs? 2017 [Available from: www.arznei-telegramm.de/html/htmlcontainer.php3?produktid=049_02&artikel=1706049_02k
  30. 30.
    Hofbauer H et al. Einsatz von Methadon zur Unterstützung der onkologischen Therapie? Der Schmerz. 2017;31(1):2–4CrossRefGoogle Scholar
  31. 31.
    Neuroonkologische Arbeitsgemeinschaft in der Deutschen Krebsgesellschaft (NOA) und Deutsche Gesellschaft für Neurologie (DGN). Gliomtherapie mit Methadon: bisher nur experimentell getestet — Wirkung beim Menschen völlig unklar 2015 [Available from: www.dgn.org/images/red_pressemitteilungen/2015/150326_Stellungnahme_NOA_DGN_Methadon_bei_Glioblastom_final.pdf
  32. 32.
    DGHO (Deutsche Gesellschaft für Hämatologie und Onkologie). Methadon bei Krebspatienten: Zweifel an Wirksamkeit und Sicherheit. Stellungnahme der DGHO DGHO Onkopedia Leitlinien2017 [Available from: www.dgho.de/informationen/stellungnahmen/gute-aerztliche-praxis/DGHO_Stellungnahme_Methadon%2020170426_.pdf
  33. 33.
    Lev R et al. Methadone related deaths compared to all prescription related deaths. Forensic science international. 2015;257:347–52CrossRefGoogle Scholar
  34. 34.
    Centers for Disease Control and Prevention. Vital signs: risk for overdose from methadone used for pain relief — United States, 1999-2010. Morbidity and Mortality Weekly Report (MMWR). 2012;61(26):493-7Google Scholar
  35. 35.
    Leitlinienprogramm Onkologie der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (AWMF) DKeVDuDKD, editor. S3-Leitlinie Palliativmedizin für Patienten mit einer nicht heilbaren Tumorerkrankung2015Google Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Constanze Rémi
    • 1
  • Claudia Bausewein
    • 2
  • Lukas Radbruch
    • 2
  1. 1.Klinik und Poliklinik für PalliativmedizinKlinikum der Universität MünchenMünchenDeutschland
  2. 2.

Personalised recommendations